EX-FILING FEES 4 ex_690763.htm EXHIBIT FILING FEES ex_690763.htm

Exhibit 107

 

Calculation of Filing Fee Tables

 

Form S-1

(Form Type)

 

NOVABAY PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

 

Security

Type

Security Class Title

Fee

Calculation

or Carry

Forward

Rule

Amount

Registered(1)

Proposed

Maximum

Offering

Price Per

Unit

Maximum

Aggregate

Offering

Price(2)

Fee Rate

Amount of

Registration Fee

Newly Registered Securities

Fees to

Be Paid

Equity

Common stock, $0.01 par value per share(3)

457(c)

298,355

$2.44

$727,986.20

0.00014760

$107.45

Fees

Previously

Paid

—

—

—

—

—

—

—

—

Carry Forward Securities

Carry

Forward

Securities

—

—

—

—

  

—

    
 

Total Offering Amounts

  

$727,986.20

  

$107.45
 

Total Fees previously Paid

      

—
 

Total Fee Offsets

      

—
 

New Fees Due

      

$107.45

 

(1)

The 298,355 shares of our common stock, par value $0.01 (“Common Stock”), being registered hereunder are being registered for sale or other distribution by the Selling Stockholders named in the prospectus that is part of this registration statement. Under Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), the shares being registered include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares being registered in this registration statement as a result of any stock splits, stock dividends or other similar events.

 

(2)

The proposed maximum offering price per share and the proposed maximum aggregate offering price have been estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(c) under the Securities Act, using the average of the high and low prices of our Common Stock as reported on the NYSE American on June 18, 2024, a date within five business days prior to the filing of this Registration Statement.

 

(3)

Consists of 298,355 shares of Common Stock issuable upon: (i) the exercise of our outstanding Series C Warrants, Series D Warrant and Series E Warrants, and (ii) the conversion of our outstanding Unsecured Convertible Notes.